ponazuril has been researched along with Disease-Models--Animal* in 4 studies
4 other study(ies) available for ponazuril and Disease-Models--Animal
Article | Year |
---|---|
Identification of Novel Positive Allosteric Modulators of Neurotrophin Receptors for the Treatment of Cognitive Dysfunction.
Alzheimer's disease (AD) is the most common neurodegenerative disorder and results in severe neurodegeneration and progressive cognitive decline. Neurotrophins are growth factors involved in the development and survival of neurons, but also in underlying mechanisms for memory formation such as hippocampal long-term potentiation. Our aim was to identify small molecules with stimulatory effects on the signaling of two neurotrophins, the nerve growth factor (NGF) and the brain derived neurotrophic factor (BDNF). To identify molecules that could potentiate neurotrophin signaling, 25,000 molecules were screened, which led to the identification of the triazinetrione derivatives ACD855 (Ponazuril) and later on ACD856, as positive allosteric modulators of tropomyosin related kinase (Trk) receptors. ACD855 or ACD856 potentiated the cellular signaling of the neurotrophin receptors with EC Topics: Age Factors; Animals; Behavior, Animal; Brain; Cell Line, Tumor; Cognition; Cognitive Dysfunction; Disease Models, Animal; Humans; Male; Maze Learning; Membrane Glycoproteins; Mice, Inbred C57BL; Motor Activity; Nootropic Agents; Protein-Tyrosine Kinases; Rats, Sprague-Dawley; Receptor, trkA; Receptor, trkB; Receptors, Nerve Growth Factor; Signal Transduction; Small Molecule Libraries; Triazines | 2021 |
Prevention of recrudescent toxoplasmic encephalitis using ponazuril in an immunodeficient mouse model.
Topics: Animals; Antiprotozoal Agents; Brain; Disease Models, Animal; Female; Immunocompromised Host; Immunohistochemistry; Liver; Lung; Male; Mice; Mice, Knockout; Secondary Prevention; Toxoplasmosis, Cerebral; Triazines | 2006 |
Ponazuril inhibits the development of Eimeria vermiformis in experimentally infected outbred Swiss mice.
We evaluated a 15% paste formulation of ponazuril in outbred Swiss mice that were experimentally infected with Eimeria vermiformis. Thirty, 8-week-old female mice (approximately 20 g) were placed in one group of 10 mice and one group of 20 mice. Mice in both groups were gavaged with approximately 5,000 sporulated oocysts of E. vermiformis on day 0. Mice in group 2 (n=10) were treated orally on days 3 and 4 with ponazuril (suspended in 30% propylene glycol) at the rate of 20 mg/kg. Mice in group 1 (n=20) were gavaged with a similar volume of 30% propylene glycol. Rates of oocyst passage (oocysts/g feces) were determined on day 10 (peak patency) for treated and nontreated mice using a fecal aliquot oocyst counting technique. Oocysts were not observed in the feces of treated mice using the aliquot technique. Control mice passaged oocysts at a geometric mean rate of >104,000 oocysts/g feces. Control mice also produced significantly less feces on day 10. These results indicate that ponazuril is effective against E. vermiformis under the conditions utilized in this study, and that the E. vermiformis mouse model could be useful in predicting the efficacy of new anticoccidial drugs. Topics: Animals; Coccidiosis; Coccidiostats; Disease Models, Animal; Eimeria; Feces; Female; Mice; Parasite Egg Count; Triazines | 2005 |
Effect of a single dose of ponazuril on neural infection and clinical disease in Sarcocystis neurona-challenged interferon-gamma knockout mice.
Interferon gamma-knockout mice were challenged with 5000 Sarcocystis neurona sporocysts acquired from a naturally infected opossum. Ponazuril was administered once, by gavage, at day 1, 3, 7, 10, or 14 post-infection (pi). Ponazuril was given at either 20 or 200mg/kg. Mice that survived to day 30 pi were euthanized. Severity of CNS infection was quantified as schizont density in the cerebellum. Unchallenged mice in treatment and non-treatment groups remained free of disease and gained weight throughout the experiment. All challenged mice, regardless of treatment, developed histologic evidence of CNS infection even though clinical signs were prevented in some groups. The greatest treatment benefits were seen in mice given 200mg/kg ponazuril between days 4 and 14 pi. Weight gain over the course of the experiment occurred only in mice that were given 200mg/kg ponazuril on day 7 or 10 pi. With the exception of groups given 200mg/kg ponazuril on day 7 or 14 pi, mice in groups that got sporocysts developed abnormal neurologic signs. No deaths before day 30 pi occurred in mice given ponazuril at 20mg/kg on day 7 pi or 200mg/kg on day 1, 7, 10, or 14 pi. This effect was not significant. Mice given 200mg/kg on day 7 pi had significantly fewer cerebellar schizonts than did those of the control group that was not given ponazuril. These results indicate that single-dose administration of ponazuril for prevention of CNS infection is partially protective when given between days 4 and 14 pi. Topics: Animals; Body Weight; Cerebellum; Disease Models, Animal; Encephalomyelitis; Female; Horse Diseases; Horses; Interferon-gamma; Mice; Mice, Inbred BALB C; Mice, Knockout; Opossums; Sarcocystis; Sarcocystosis; Triazines | 2003 |